1887

Microbial Genomics logo

Volume 9, Issue 3

Advantages of analysing both pairwise SNV-distance and differing SNVs between isolates for recurrent tuberculosis cause determination Open Access

Abstract

Endogenous reactivation and exogenous reinfection are two possible causes of recurrent tuberculosis (TB). However, in some cases, precise cause determination can be challenging. In this study, we used whole genome sequencing to determine pairwise SNV distances and detect differing SNVs in initial and subsequent isolates for recurrent TB cases when the first and second episodes were caused by () strains with an identical spoligotype pattern. In total, 104 isolates from 36 recurrent TB and 16 single TB episode patients were included in the study. Most isolate pairs belonged to the SIT1 (n=21), SIT42 (n=9), SIT53 (n=9), and SIT254 (n=7) spoligotypes, and in 27 cases, resistance to at least one anti-TB drug was found in either isolate. Drug susceptibility was more common in the recurrent TB patient cohort, and longitudinal single TB episode isolates were more prone to be drug-resistant (p=0.03), while the association between patient cohort and spoligotype was not statistically significant (p=0.07). The pairwise SNV-distance between the longitudinal single TB episode isolates was small (0-7 SNVs). Among the recurrent TB isolates, based on the high SNV-distance (38–273 SNVs), six reinfection cases (16.7%) were identified. This distance was small (<10 SNVs) in the remaining 30 isolate pairs. Further analysis of differing SNVs revealed that 22 (61.1%) cases could be classified as possible reactivation. Notably, despite the small distance of 2–7 SNVs, initial isolates of eight patients (22.2%) had several SNVs that were not found in the second isolates; therefore, these cases were classified as reinfection with a closely related strain. No statistically significant difference in the time interval between specimen collection in the reactivation and reinfection sample groups (p=0.13) or an association between recurrence cause and drug resistance status (p=0.62) or spoligotype (p=0.79) could be detected. The mycobacterial median mutation rate of longitudinal single TB episodes and possible reactivation isolate pairs (n=37) was 0.12 SNVs/genome/year (IQR 0-0.39), and in 18 cases (48.6%), it was equal to zero. No statistically significant differences in mutation rate were found between recurrent TB and longitudinal single TB episode isolates (p=0.087), drug-susceptible and resistant isolates (p=0.37) or isolates of Beijing and other genotype families (p=0.33). Furthermore, four cases of fluoroquinolone resistance development through the acquired SNVs in the gene were identified. To conclude, this study highlighted the complexity of recurrent episode cause determination and showed the usefulness of differing SNV identification in both isolates in such cases. Expected drug susceptibility was the only discriminative factor for recurrent TB episode-causing mycobacterial strains, while no differences between reactivation and reinfection sample groups could be identified.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): reactivation , recurrence , reinfection , tuberculosis and whole genome sequencing
Funding
This study was supported by the:
  • European Regional Development Fund (Award 1.1.1.1/20/A/046)
    • Principle Award Recipient: RenāteRanka
© 2023 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/mgen/10.1099/mgen.0.000956
2023-03-23
2024-04-27
Loading full text...

Full text loading...

/deliver/fulltext/mgen/9/3/mgen000956.html?itemId=/content/journal/mgen/10.1099/mgen.0.000956&mimeType=html&fmt=ahah

References

  1. World Health Organization Global tuberculosis report 2021. Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO 2021
     [Google Scholar]
  2. World Health Organization Implementing the end TB strategy: the essentials. Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO 2015
     [Google Scholar]
  3. World Health Organization Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions 17-19 November 2020. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO 2020
     [Google Scholar]
  4. McIvor A, Koornhof H, Kana BD. Relapse, re-infection and mixed infections in tuberculosis disease. Pathog Dis 2017; 75: [View Article] [PubMed]
     [Google Scholar]
  5. Warren RM, Streicher EM, Charalambous S, Churchyard G, van der Spuy GD et al. Use of spoligotyping for accurate classification of recurrent tuberculosis. J Clin Microbiol 2002; 40:3851–3853 [View Article] [PubMed]
     [Google Scholar]
  6. Dobler CC, Marks GB, Simpson SE, Crawford ABH. Recurrence of tuberculosis at a Sydney chest clinic between 1994 and 2006: reactivation or reinfection?. Med J Aust 2008; 188:153–155 [View Article]
     [Google Scholar]
  7. Zong Z, Huo F, Shi J, Jing W, Ma Y et al. Relapse versus reinfection of recurrent tuberculosis patients in a national tuberculosis specialized hospital in Beijing, China. Front Microbiol 2018; 9:1858 [View Article]
     [Google Scholar]
  8. Luzze H, Johnson DF, Dickman K, Mayanja-Kizza H, Okwera A et al. Relapse more common than reinfection in recurrent tuberculosis 1-2 years post treatment in urban Uganda. Int J Tuberc Lung Dis 2013; 17:361–367 [View Article] [PubMed]
     [Google Scholar]
  9. Meehan CJ, Goig GA, Kohl TA, Verboven L, Dippenaar A et al. Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues. Nat Rev Microbiol 2019; 17:533–545 [View Article] [PubMed]
     [Google Scholar]
  10. Witney AA, Bateson ALE, Jindani A, Phillips PPJ, Coleman D et al. Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trial. BMC Med 2017; 15:71 [View Article]
     [Google Scholar]
  11. Korhonen V, Smit PW, Haanperä M, Casali N, Ruutu P et al. Whole genome analysis of Mycobacterium tuberculosis isolates from recurrent episodes of tuberculosis, Finland, 1995-2013. Clin Microbiol Infect 2016; 22:549–554 [View Article] [PubMed]
     [Google Scholar]
  12. Parvaresh L, Crighton T, Martinez E, Bustamante A, Chen S et al. Recurrence of tuberculosis in a low-incidence setting: a retrospective cross-sectional study augmented by whole genome sequencing. BMC Infect Dis 2018; 18:265 [View Article]
     [Google Scholar]
  13. Guerra-Assunção JA, Houben RMGJ, Crampin AC, Mzembe T, Mallard K et al. Recurrence due to relapse or reinfection with Mycobacterium tuberculosis: a whole-genome sequencing approach in a large, population-based cohort with a high HIV infection prevalence and active follow-up. J Infect Dis 2015; 211:1154–1163 [View Article] [PubMed]
     [Google Scholar]
  14. Bryant JM, Harris SR, Parkhill J, Dawson R, Diacon AH et al. Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study. Lancet Respir Med 2013; 1:786–792 [View Article] [PubMed]
     [Google Scholar]
  15. Han Z, Li J, Sun G, Gu K, Zhang Y et al. Transmission of multidrug-resistant tuberculosis in Shimen community in Shanghai, China: a molecular epidemiology study. BMC Infect Dis 2021; 21:1118 [View Article]
     [Google Scholar]
  16. Walker TM, Lalor MK, Broda A, Ortega LS, Morgan M et al. Assessment of Mycobacterium tuberculosis transmission in Oxfordshire, UK, 2007-12, with whole pathogen genome sequences: an observational study. Lancet Respir Med 2014; 2:285–292 [View Article] [PubMed]
     [Google Scholar]
  17. Guerra-Assunção JA, Crampin AC, Houben RMGJ, Mzembe T, Mallard K et al. Large-scale whole genome sequencing of M. tuberculosis provides insights into transmission in a high prevalence area. Elife 2015; 4:e05166 [View Article]
     [Google Scholar]
  18. Dippenaar A, De Vos M, Marx FM, Adroub SA, van Helden PD et al. Whole genome sequencing provides additional insights into recurrent tuberculosis classified as endogenous reactivation by IS6110 DNA fingerprinting. Infect Genet Evol 2019; 75:103948 [View Article] [PubMed]
     [Google Scholar]
  19. Pérez-Lago L, Monteserin J, Paul R, Maus SR, Yokobori N et al. Recurrences of multidrug-resistant tuberculosis: strains involved, within-host diversity, and fine-tuned allocation of reinfections. Transbound Emerg Dis 2022; 69:327–336 [View Article]
     [Google Scholar]
  20. Folkvardsen DB, Norman A, Rasmussen EM, Lillebaek T, Jelsbak L et al. Recurrent tuberculosis in patients infected with the predominant Mycobacterium tuberculosis outbreak strain in Denmark. New insights gained through whole genome sequencing. Infect Genet Evol 2020; 80:104169 [View Article] [PubMed]
     [Google Scholar]
  21. Wollenberg K, Harris M, Gabrielian A, Ciobanu N, Chesov D et al. A retrospective genomic analysis of drug-resistant strains of M. tuberculosis in a high-burden setting, with an emphasis on comparative diagnostics and reactivation and reinfection status. BMC Infect Dis 2020; 20:17 [View Article]
     [Google Scholar]
  22. World Health Organisation WHO global lists of high burden countries for tuberculosis (TB) TB/HIV and multidrug/rifampicin-resistant TB (MDR/RR-TB), 2021-2025. Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO 2021
     [Google Scholar]
  23. World Health Organisation Tuberculosis profile: Latvia. n.d https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&entity_type=%22country%22&lan=%22EN%22&iso2=%22LV%22
  24. Pole I, Trofimova J, Norvaisa I, Supply P, Skenders G et al. Analysis of Mycobacterium tuberculosis genetic lineages circulating in Riga and Riga region, Latvia, isolated between 2008 and 2012. Infect Genet Evol 2020; 78:104126 [View Article] [PubMed]
     [Google Scholar]
  25. Kuksa L, Riekstina V, Leimane V, Ozere I, Skenders G et al. Multi- and extensively drug-resistant tuberculosis in Latvia: trends, characteristics and treatment outcomes. Public Health Action 2014; 4:S47–53 [View Article] [PubMed]
     [Google Scholar]
  26. van Soolingen D, Hermans PW, de Haas PE, Soll DR, van Embden JD. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol 1991; 29:2578–2586 [View Article] [PubMed]
     [Google Scholar]
  27. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997; 35:907–914 [View Article] [PubMed]
     [Google Scholar]
  28. Afgan E, Baker D, Batut B, van den Beek M, Bouvier D et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. Nucleic Acids Res 2018; 46:W537–W544 [View Article] [PubMed]
     [Google Scholar]
  29. van Heusden P, Gladman S, Lose T. M. tuberculosis variant analysis (galaxy training materials). n.d https://training.galaxyproject.org/training-material/topics/variant-analysis/tutorials/tb-variant-analysis/tutorial.html
  30. Comas I, Chakravartti J, Small PM, Galagan J, Niemann S et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet 2010; 42:498–503 [View Article] [PubMed]
     [Google Scholar]
  31. World Health Organisation WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO 2019
     [Google Scholar]
  32. World Health Organisation Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis 27-29 October 2020. Geneva: World Health Organization. CC BY-NC-SA 3.0 IGO 2021
     [Google Scholar]
  33. Buu TN, Huyen MN, Lan NTN, Quy HT, Hen NV et al. The Beijing genotype is associated with young age and multidrug-resistant tuberculosis in rural Vietnam. Int J Tuberc Lung Dis 2009; 13:900–906 [PubMed]
     [Google Scholar]
  34. San LL, Aye KS, Oo NAT, Shwe MM, Fukushima Y et al. Insight into multidrug-resistant Beijing genotype Mycobacterium tuberculosis isolates in Myanmar. Int J Infect Dis 2018; 76:109–119 [View Article] [PubMed]
     [Google Scholar]
  35. Li D, Song Y, Yang P, Li X, Zhang A-M et al. Genetic diversity and drug resistance of Mycobacterium tuberculosis in Yunnan, China. J Clin Lab Anal 2019; 33:e22884 [View Article]
     [Google Scholar]
  36. Couvin D, Rastogi N. Tuberculosis - A global emergency: tools and methods to monitor, understand, and control the epidemic with specific example of the Beijing lineage. Tuberculosis 2015; 95 Suppl 1:S177–89 [View Article]
     [Google Scholar]
  37. Imperiale BR, Zumárraga MJ, Di Giulio AB, Cataldi AA, Morcillo NS. Molecular and phenotypic characterisation of Mycobacterium tuberculosis resistant to anti-tuberculosis drugs. Int J Tuberc Lung Dis 2013; 17:1088–1093 [View Article] [PubMed]
     [Google Scholar]
  38. Ordaz-Vázquez A, Torres-González P, Cruz-Hervert P, Ferreyra-Reyes L, Delgado-Sánchez G et al. Genetic diversity and primary drug resistance transmission in Mycobacterium tuberculosis in southern Mexico. Infect Genet Evol 2021; 93:104994 [View Article] [PubMed]
     [Google Scholar]
  39. Grandjean L, Iwamoto T, Lithgow A, Gilman RH, Arikawa K et al. The association between Mycobacterium tuberculosis genotype and drug resistance in Peru. PLoS One 2015; 10:e0126271 [View Article]
     [Google Scholar]
  40. Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. Eur Respir J 2019; 54:1901522 [View Article]
     [Google Scholar]
  41. Ahmad N, Ahuja SD, Akkerman OW, Alffenaar J-WC, Anderson LF et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet 2018; 392:821–834 [View Article]
     [Google Scholar]
  42. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med 2020; 382:893–902 [View Article]
     [Google Scholar]
  43. Alene KA, Yi H, Viney K, McBryde ES, Yang K et al. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China. BMC Infect Dis 2017; 17:573 [View Article]
     [Google Scholar]
  44. Liu Q, Wang D, Martinez L, Lu P, Zhu L et al. Mycobacterium tuberculosis Beijing genotype strains and unfavourable treatment outcomes: a systematic review and meta-analysis. Clin Microbiol Infect 2020; 26:180–188 [View Article]
     [Google Scholar]
  45. Brown AC, Bryant JM, Einer-Jensen K, Holdstock J, Houniet DT et al. Rapid whole-genome sequencing of Mycobacterium tuberculosis isolates directly from clinical samples. J Clin Microbiol 2015; 53:2230–2237 [View Article]
     [Google Scholar]
  46. Genestet C, Hodille E, Westeel E, Ginevra C, Ader F et al. Subcultured Mycobacterium tuberculosis isolates on different growth media are fully representative of bacteria within clinical samples. Tuberculosis 2019; 116:61–66 [View Article]
     [Google Scholar]
  47. Hatherell H-A, Didelot X, Pollock SL, Tang P, Crisan A et al. Declaring a tuberculosis outbreak over with genomic epidemiology. Microb Genom 2016; 2:e000060 [View Article]
     [Google Scholar]
  48. Bryant JM, Schürch AC, van Deutekom H, Harris SR, de Beer JL et al. Inferring patient to patient transmission of Mycobacterium tuberculosis from whole genome sequencing data. BMC Infect Dis 2013; 13:110 [View Article]
     [Google Scholar]
  49. Walker TM, Ip CLC, Harrell RH, Evans JT, Kapatai G et al. Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis 2013; 13:137–146 [View Article]
     [Google Scholar]
  50. Hakamata M, Takihara H, Iwamoto T, Tamaru A, Hashimoto A et al. Higher genome mutation rates of Beijing lineage of Mycobacterium tuberculosis during human infection. Sci Rep 2020; 10:17997 [View Article]
     [Google Scholar]
  51. Lillebaek T, Norman A, Rasmussen EM, Marvig RL, Folkvardsen DB et al. Substantial molecular evolution and mutation rates in prolonged latent Mycobacterium tuberculosis infection in humans. Int J Med Microbiol 2016; 306:580–585 [View Article] [PubMed]
     [Google Scholar]
  52. Ford CB, Lin PL, Chase MR, Shah RR, Iartchouk O et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 2011; 43:482–486 [View Article] [PubMed]
     [Google Scholar]
  53. Colangeli R, Arcus VL, Cursons RT, Ruthe A, Karalus N et al. Whole genome sequencing of Mycobacterium tuberculosis reveals slow growth and low mutation rates during latent infections in humans. PLoS One 2014; 9:e91024 [View Article]
     [Google Scholar]
  54. Allué-Guardia A, García JI, Torrelles JB. Evolution of drug-resistant Mycobacterium tuberculosis strains and their Adaptation to the human lung environment. Front Microbiol 2021; 12:612675 [View Article]
     [Google Scholar]
  55. Umarje SP, Alexander CG, Cohen AJ. Ambulatory fluoroquinolone use in the United States, 2015-2019. Open Forum Infect Dis 2021; 8:ofab538 [View Article]
     [Google Scholar]
  56. Ginsburg AS, Woolwine SC, Hooper N, Benjamin WH, Bishai WR et al. The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med 2003; 349:1977–1978 [View Article]
     [Google Scholar]
  57. Chen TC, Lu PL, Lin CY, Lin WR, Chen YH. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis 2011; 15:e211–6 [View Article] [PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/mgen/10.1099/mgen.0.000956
Loading
Advantages of analysing both pairwise SNV-distance and differing SNVs between Mycobacterium tuberculosis isolates for recurrent tuberculosis cause determination
M Gen 9, 000956 (2023); https://doi.org/10.1099/mgen.0.000956
/content/journal/mgen/10.1099/mgen.0.000956
/content/journal/mgen/10.1099/mgen.0.000956
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error